EUVIMEDEUVIMED entdecken
Crossref

Major Bleeding Risk During Concomitant Use of Antiarrhythmic Drugs and Oral Factor Xa Inhibitors: A Nationwide Self-Controlled Case Series Study

Yoojung Choi, Jonghyun Jeong, Kyu-Nam Heo, Jaekyu Shin, Ju-Yeun Lee

Thrombosis and Haemostasis · 01.07.2026 · 126 (07) · 743-753

DOI: 10.1055/a-2679-6101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.07.2026. Verfasst von Yoojung Choi und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Seoul National University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Hemorrhage, Factor Xa Inhibitors, Anti-Arrhythmia Agents. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Ministry of Health & Welfare, Republic of Korea, Ministry of Science and ICT of the Government of Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bleeding risk may increase when factor Xa (FXa) inhibitors are co-administered with antiarrhythmic drugs (AADs) due to pharmacokinetic interactions, but real-world evidence on these interactions is inconsistent and limited, particularly for edoxaban. The aim of this study was to evaluate the overall and temporal risk of major bleeding associated with concomitant use of AADs (amiodarone, dronedarone, diltiazem, verapamil) and FXa inhibitors (apixaban, edoxaban, rivaroxaban) using the self-controlled case series (SCCS) method. An SCCS study was conducted using the Korean National Health Insurance Service database. Patients who initiated FXa inhibitors between July 2018 and December 2020, had AAD co-administration, and experienced major bleeding were included. Incidence rate ratios (IRRs) for major bleeding were estimated using conditional Poisson regression, adjusting for time-varying covariates. A total of 963 patients were analyzed. Concomitant use of amiodarone (IRR 2.16; 95% CI 1.73–2.70), diltiazem (IRR 1.96; 95% CI 1.63–2.35), and verapamil (IRR 1.72; 95% CI 1.15–2.59) was associated with an increased major bleeding risk, while dronedarone was not (IRR 1.20; 95% CI 0.69–2.06). The findings were consistent across different FXa inhibitors. Bleeding risk was highest during the first month of co-administration and decreased over time, remaining significant beyond 3 months for amiodarone. Concomitant use of FXa inhibitors with amiodarone, diltiazem, or verapamil was related to an increased incidence of major bleeding, particularly during the first month of co-administration. Close monitoring during this period may be warranted for patients at high risk of bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemorrhageFactor Xa InhibitorsAnti-Arrhythmia AgentsHumansFemaleMaleAgedMiddle AgedRisk FactorsDrug InteractionsRepublic of KoreaAdministration, OralIncidenceRisk AssessmentDrug Therapy, CombinationAdultDiltiazemAged, 80 and overVerapamil

Substanzen

Factor Xa InhibitorsAnti-Arrhythmia AgentsDiltiazemVerapamil

Autor:innen und Institutionen

  • College of Pharmacy, Seoul National University, Seoul, Republic of Korea.
  • Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Republic of Korea.
  • Department of Clinical Pharmacy, University of California-San Francisco, San Francisco, United States.

Förderung

  • Ministry of Health & Welfare, Republic of Korea
  • Ministry of Science and ICT of the Government of Republic of Korea

Zitieren

APA

Choi, Y., Jeong, J., Heo, K. N., Shin, J., & Lee, J. Y. (2026). Major Bleeding Risk During Concomitant Use of Antiarrhythmic Drugs and Oral Factor Xa Inhibitors: A Nationwide Self-Controlled Case Series Study. Thrombosis and Haemostasis, 126(07), 743-753. https://doi.org/10.1055/a-2679-6101

Vancouver

Choi Y, Jeong J, Heo KN, Shin J, Lee JY. Major Bleeding Risk During Concomitant Use of Antiarrhythmic Drugs and Oral Factor Xa Inhibitors: A Nationwide Self-Controlled Case Series Study. Thrombosis and Haemostasis. 2026;126(07):743-753. doi:10.1055/a-2679-6101

BibTeX
@article{Choi2026,
  author = {Choi, Yoojung and Jeong, Jonghyun and Heo, Kyu-Nam and Shin, Jaekyu and Lee, Ju-Yeun},
  title = {Major Bleeding Risk During Concomitant Use of Antiarrhythmic Drugs and Oral Factor Xa Inhibitors: A Nationwide Self-Controlled Case Series Study},
  journal = {Thrombosis and Haemostasis},
  year = {2026},
  volume = {126},
  number = {07},
  pages = {743--753},
  doi = {10.1055/a-2679-6101}
}
Kostenlos starten →